Lantheus Holdings has appointed Paul Blanchfield to serve as its chief commercial officer. Blanchfield was most recently head of US immunology at Japan’s Takeda Pharmaceutical (NYSE: [[ticker:TAK]]). Before, he held several different roles at Dublin, Ireland-based Shire, which Takeda acquired in January 2019. North Billerica, MA-based Lantheus Holdings is the parent company of LMI, a company that makes diagnostic imaging agents and products.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
